Omeros Corporation (OMER)
| Previous Close | 3.5300 |
| Open | 3.5200 |
| Bid | 3.4600 x 100 |
| Ask | 3.5600 x 100 |
| Day's Range | 3.3157 - 3.6200 |
| 52 Week Range | 0.9200 - 7.8000 |
| Volume | |
| Avg. Volume | 441,809 |
| Market Cap | 203.674M |
| Beta (5Y Monthly) | 1.33 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.7900 |
| Earnings Date | May 09, 2024 - May 13, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 43.00 |
Business WireOmeros Corporation Announces Upcoming Presentations at 2024 European Hematology Association (EHA) Hybrid Congress
SEATTLE, May 09, 2024--Omeros Corporation (Nasdaq: OMER) today announced that interim analysis data from its ongoing Phase 2 study of OMS906 in patients with paroxysmal nocturnal hemoglobinuria submitted to the 2024 European Hematology Association (EHA) Hybrid Congress has been selected for podium presentation. The EHA Congress will be held June 13-16, 2024, in Madrid, Spain. OMS906 is Omeros’ investigational inhibitor of MASP-3 targeting the alternative pathway of complement. Two additional pos
Insider MonkeyOmeros Corporation (NASDAQ:OMER) Q4 2023 Earnings Call Transcript
Omeros Corporation (NASDAQ:OMER) Q4 2023 Earnings Call Transcript April 1, 2024 Omeros Corporation isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good afternoon and welcome to today’s conference call from Omeros Corporation. At this time, all participants are in a […]
